Replies to post #46315 on Biotech Values

[dewophile]

rprx
I think there is some fast money buying in advance of the final endometriosis data and the biopsy results from the fibroid trial. I also think there is even more money (including possibly pharma suitors) waiting on the biopsy results

[zipjet]

>>rprx is significantly undervalued here...

Agreed.

I think that MNTA is also significantly undervalued.

Each of these two companies carry significant risks but appear to have more than compensating potential returns. Each has the potential to be a 4 bagger. (An educated guess.)

zip